All PlansCoverageHigh impact
Autologous Chondrocyte Implantation (ACI) - (Effective Date - 2026-10-15) 7.01.38
Excellus BlueCross BlueShield·Orthopedics, Sports Medicine·Bone & Joints (Orthopedic)
Effective date
Oct 15, 2026
We identified it
Jul 16, 2026
Summary
Excellus BlueCross BlueShield has issued a new medical policy (7.01.38, effective October 15, 2026) establishing specific medical necessity criteria for Autologous Chondrocyte Implantation (ACI/MACI) procedures on the knee. The policy defines strict patient eligibility (age 15-55, BMI ≤35), imaging/arthroscopic requirements (Kellgren-Lawrence Grade II or less, full-thickness defects 1-10cm²), and mandates 3+ months of failed conservative treatment. Claims not meeting ALL criteria will be denied. Additionally, Hybrid ACI/OATS procedures are classified as investigational and not covered.
Action Required
By October 15, 2026: Billing team must implement prior authorization requirements for all ACI/MACI procedures. (1) Update billing software to flag ACI claims for mandatory medical necessity review before submission. (2) Providers must document in the medical record: BMI, patient age, Kellgren-Lawrence grade, Outerbridge classification (imaging method used), cartilage defect size in cm², confirmation of normal cartilage at lesion borders, knee stability exam findings, ligament/meniscal status, tibial-femoral alignment, and proof of ≥3 months non-surgical management with specific interventions attempted. (3) Create pre-authorization checklist for front-desk/billing staff to verify all 8 criteria (A-H) are met before claim submission. (4) Deny and educate providers on any claims for: patients outside age 15-55 range, BMI >35, presence of inflammatory arthritis, Kellgren-Lawrence Grade III+, osteochondritis dissecans requiring bone grafting, kissing lesions (Grade III/IV), unstable knee/ligament insufficiency, abnormal alignment, any knee surgery within 6 months prior (except biopsy/prep), total meniscectomy, septic arthritis history, aminoglycoside/porcine/bovine hypersensitivity, blood coagulation disorders, or cruciate ligament instability. (5) Do NOT cover Hybrid ACI/OATS procedures—deny these claims and inform providers this technique remains investigational. Failure to implement authorization controls will result in widespread claim denials and compliance violations.